Literature DB >> 34006168

Regulation of the apolipoprotein M signaling pathway: a review.

Gangli Cheng1, Lu Zheng1.   

Abstract

Apolipoprotein M (apoM), an apolipoprotein predominantly associated with high-density lipoprotein (HDL), is considered a mediator of the numerous roles of HDL, including reverse cholesterol transport, anti-atherosclerotic, anti-inflammatory and anti-oxidant, and mediates pre-β-HDL formation. ApoM expression is known to be regulated by a variety of in vivo and in vitro factors. The transcription factors farnesoid X receptor, small heterodimer partner, liver receptor homolog-1, and liver X receptor comprise the signaling cascade network that regulates the expression and secretion of apoM. Moreover, hepatocyte nuclear factor-1α and c-Jun/JunB have been demonstrated to exert opposing regulatory effects on apoM through competitive binding to the same sites in the proximal region of the apoM gene. Furthermore, as a carrier and modulator of sphingosine 1-phosphate (S1P), apoM binds to S1P within its hydrophobic-binding pocket. The apoM/S1P axis has been discovered to play a crucial role in the apoM signaling pathway through its ability to regulate glucose and lipid metabolism, vascular barrier homeostasis, inflammatory response and other pathological and physiological processes. Using the findings of previous studies, the present review aimed to summarize the regulation of apoM expression by various factors and its role in different physiological and pathological conditions, and provide a new perspective for the further treatment of these diseases.

Entities:  

Keywords:  Apolipoprotein M; high-density lipoprotein; signaling pathway; sphingosine 1-phosphate; transcription factor

Mesh:

Substances:

Year:  2021        PMID: 34006168     DOI: 10.1080/10799893.2021.1924203

Source DB:  PubMed          Journal:  J Recept Signal Transduct Res        ISSN: 1079-9893            Impact factor:   2.092


  2 in total

1.  HDL-Associated Lipoproteins: Potential Prognostic Biomarkers for Gram-Negative Sepsis.

Authors:  Guoying Zou; Qing Zhu; Biqiong Ren; Qi Guo; Yuanyuan Wu; Junyu He; Ying Wu; Zhihong Luo
Journal:  J Inflamm Res       Date:  2022-02-17

2.  Hypercholesterolemia-Induced HDL Dysfunction Can Be Reversed: The Impact of Diet and Statin Treatment in a Preclinical Animal Model.

Authors:  Leonie Schoch; Pablo Sutelman; Rosa Suades; Laura Casani; Teresa Padro; Lina Badimon; Gemma Vilahur
Journal:  Int J Mol Sci       Date:  2022-08-02       Impact factor: 6.208

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.